• Profile
Close

Trial of pimavanserin in dementia-related psychosis

New England Journal of Medicine Jul 28, 2021

Tariot PN, Cummings JL, Soto-Martin ME, et al. - Dementia-related psychosis may be present in patients with dementia due to neurodegenerative disease. Researchers examined how oral 5-HT2A inverse agonist and antagonist pimavanserin affects psychosis related to various causes of dementia. In this phase 3, double-blind, randomized, placebo-controlled discontinuation trial, they included patients with psychosis related to Alzheimer’s disease, Parkinson’s disease dementia, dementia with Lewy bodies, frontotemporal dementia, or vascular dementia. This trial was stopped early for efficacy. Patients with dementia-related psychosis who had a response to pimavanserin were noted to be at a lower risk of relapse with continuation of the drug than with discontinuation.

Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay